Overview

Fontan Udenafil Exercise Longitudinal Assessment Trial

Status:
Completed

Trial end date:
2019-04-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent subjects who have undergone the Fontan procedure.

Phase:

Phase 3

Details

Lead Sponsor:

Mezzion Pharma Co. Ltd

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Udenafil